

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 5)*

Adamas Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value

(Title of Class of Securities)

00548A 106

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

1 Names of Reporting Persons

Gregory T. Went

2 Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3 SEC Use Only

4 Citizenship or Place of Organization

United States

5 Sole Voting Power

1,447,441¹

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With:

6 Shared Voting Power

0

7 Sole Dispositive Power

1,447,441¹

8 Shared Dispositive Power

0

9 Aggregate Amount Beneficially Owned by Each Reporting Person

1,447,441¹

10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11 Percent of Class Represented by Amount in Row 9

4.97%

12 Type of Reporting Person (See Instructions)

IN

¹ Includes 1,183,628 shares subject to options exercisable within 60 days of December 31, 2019 and 51,650 shares held By Trust. Dr. Went is the sole trustee of the trusts and is deemed to have sole voting and dispositive power with respect to all shares held by the trusts.

Item 1(a). Name of Issuer
Adamas Pharmaceuticals, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices
1900 Powell St, Suite 1000
Emeryville, CA 94608

Item 2(a). Name of Person Filing
Gregory T. Went

Item 2(b). Address of Principal Business Office or, if none, Residence
The address for the principal business office of Gregory T. Went is:
2251 Washington St.
San Francisco, CA 94115

Item 2(c). Citizenship
United States

Item 2(d). Title of Class of Securities
Common Stock, par value \$0.001

Item 2(e). CUSIP Number
00548A 106

Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
- (k) Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _____

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)	Amount beneficially owned	1,447,441 ²
(b)	Percent of class	4.97%
(c)	Number of shares as to which the person has:	
	(i) Sole power to vote or to direct the vote	1,447,441 ²
	(ii) Shared power to vote or to direct the vote	0
	(iii) Sole power to dispose or to direct the disposition of	1,447,441 ²
	(iv) Shared power to dispose or to direct the disposition of	0

Item 5. Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following .

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable.

Item 8. Identification and Classification of Members of the Group

Not applicable.

Item 9. Notice of Dissolution of a Group

Not applicable.

Item 10. Certification

Not applicable.

² Includes 1,183,628 shares subject to options exercisable within 60 days of December 31, 2019, and 51,650 shares held by the Trusts.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2020

Date

/s/ Gregory T. Went

Gregory T. Went